However, a few potential mechanisms can be speculated based on the findings in tumor-specific targeting of the death receptor (DR)-4 and DR-5 agonistic mAb therapy despite the presence of DR-4/DR-5 in normal cells [113,114,115]. This evidence concerns the gene TNFRSF10B and neoplasm.